SIG
52
5
MSFT
55
2
EQT
47
13
ROST
60
3
ADBE
50
3
PWR
63
3
ORLY
48
3
GS
65
16
BAX
38
2
GT
43
2
JWN
72
9
ZBH
69
15
GE
60
5
CSCO
63
5
MAT
41
2
R
55
-2
EBAY
42
2
SYF
78
7
EQR
33
6
BIIB
36
8
SIG
52
5
MSFT
55
2
EQT
47
13
ROST
60
3
ADBE
50
3
PWR
63
3
ORLY
48
3
GS
65
16
BAX
38
2
GT
43
2
JWN
72
9
ZBH
69
15
GE
60
5
CSCO
63
5
MAT
41
2
R
55
-2
EBAY
42
2
SYF
78
7
EQR
33
6
BIIB
36
8
Financhill
Back

Edgewise Therapeutics Stock Predictions

These 7 Stocks Will Be Magnificent in 2025

Get Your Copy of "These 7 Stocks Will Be Magnificent in 2025" Here.
Sell
48

EWTX
Edgewise Therapeutics

Last Price:
$30.27
Seasonality Move:
26.98%

7 Day Trial

ALL ACCESS PASS

$ 7

Elon Musk Predicts MAJOR Crisis in Trump's First Year

See Why Investors are Pouring Mountains of Cash into Certain Companies Trump Wants to Solve the Problem.

Edgewise Therapeutics Stock Forecast

  • Over the next 52 weeks, Edgewise Therapeutics has on average historically risen by 96.7% based on the past 3 years of stock performance.
  • Edgewise Therapeutics has risen higher in 1 of those 3 years over the subsequent 52-week period, corresponding to a historical accuracy of 33.33%
  • Is Edgewise Therapeutics Stock Undervalued?
    The current Edgewise Therapeutics [EWTX] share price is $30.74. The Score for EWTX is 48, which is 4% below its historic median score of 50, and infers higher risk than normal.
  • EWTX is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.

Will Edgewise Therapeutics Stock Go Up Next Year?

  • Over the next 52 weeks, Edgewise Therapeutics has on average historically risen by 96.7% based on the past 3 years of stock performance.

Edgewise Therapeutics Stock Rating

Sell
48
Edgewise Therapeutics (EWTX) is a Sell

Is Edgewise Therapeutics overpriced?

  • Edgewise Therapeutics has risen higher in 1 of those 3 years over the subsequent 52-week period, corresponding to a historical accuracy of 33.33%

Edgewise Therapeutics Stock Price History

Is EWTX stock going to rise?

  • The current trend is relatively stagnant and EWTX is experiencing slight selling pressure.

Stock Information

Stock Info

Exchange:
NASDAQ
Country:
United States
Industry:
Pharmaceuticals
Sector:
Health Care
Type:
stock
Website:
edgewisetx.com

52-Week Data

52-Week High:
38.12
52-Week Low:
9.00

Prediction Charts

Market Cap:
2.9B
Price in USD:
30.74
Volume:
1.1M
Beta:
0.13

Technical Analysis

SMA50:
32.69
SMA100:
26.72
SMA200:
22.37
52-Wk Change:
261.22%

Stock Predictions

  • Is Edgewise Therapeutics stock public?
    Yes, Edgewise Therapeutics is a publicly traded company.
  • What is the Edgewise Therapeutics stock quote today?
    The Edgewise Therapeutics stock price is 30.74 USD today.
  • How to buy Edgewise Therapeutics stock online?
    You can buy Edgewise Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

14-Day Historical Data

Date Opening Closing Minimum Maximum
Dec-3 31.34 31.96 32.26 30.89
Dec-4 31.96 32.06 32.82 31.56
Dec-5 31.71 31.57 31.95 29.88
Dec-6 31.52 32.59 33.55 31.47
Dec-9 32.78 30.24 32.89 29.66
Dec-10 30.24 29.46 30.83 28.91
Dec-11 29.92 29.80 30.39 29.38
Dec-12 29.76 28.15 30.02 27.00
Dec-13 28.50 27.62 29.00 27.52
Dec-16 28.20 32.69 35.50 28.00
Dec-17 33.37 30.17 33.38 29.97
Dec-18 30.05 30.01 31.41 29.94
Dec-19 30.41 30.80 30.87 29.39
Dec-20 30.54 30.74 32.61 30.06

Edgewise Therapeutics Earnings

Edgewise Therapeutics Earnings Report: Per Share Edgewise Therapeutics Earnings Q1 Q2 Q3 and Q4 last year and next year.

Edgewise Therapeutics Forecast Revenue Growth

Edgewise Therapeutics Stock Analysis: Historical quarterly revenues per share for Edgewise Therapeutics and historical quarterly revenue growth:

  • Analysts estimate an earnings increase this quarter of $0.06 per share, a decrease next quarter of $0.00 per share, an increase this year of $0.04 per share, and a decrease next year of $0.30 per share.

* Edgewise Therapeutics stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.